Eugene serves as Co-Head of Healthcare Investment Banking and U.S. Head of Biotechnology and Specialty Pharmaceuticals, focused on mergers and acquisitions and capital raising transactions. He joined us in 2010 to enhance our emerging therapeutics sector focus, bringing over 19 years of significant life sciences investment banking experience at HSBC, Wells Fargo, and Robertson Stephens. He has advised clients on a wide variety of corporate finance and strategic assignments, including mergers & acquisitions, IPOs, public offerings and private placements of debt and equity securities, PIPEs and LBOs for both public and private companies. Eugene graduated from the Leonard N. Stern School of Business at New York University with an MBA and a degree in Biology from New York University.
Selected Transactions
-
US$30m
Sesen Bio Inc.
Sole Bookrunner (CMPO)
-
US$163m
Stoke Therapeutics
Lead Manager (IPO)
-
US$135m
Fibrocell Science, Inc.
Financial Advisor for Fibrocell Science, Inc. on its collaboration agreement with Castle Creek Pharmaceuticals
-
US$110m
Y-mAbs Therapeutics
Lead Manager (IPO)
-
US$46m
Sesen
Joint Bookrunner (Follow-on Offering)
-
US$49m
VBI Vaccines Inc.
Joint Bookrunner (Follow-on)
-
US$20m
Summit Therapeutics
Joint Bookrunner (CMPO)
-
US$12m
Contravir
Sole Bookrunner (Follow-on)
-
US$17m
Galena Biopharma
Sole Bookrunner (Follow-on Offering)
